Search Results

Meiji Seika Pharma Co., Ltd. announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis conducted in the United States and Canada were presented on 12 October at the European Association of Dermatology and Venereology Congress 2023 held in Berlin.

Meiji Seika Pharma Co., Ltd. announced that ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index, in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.

Meiji Seika Pharma Co., Ltd. and the Foundation for Biomedical Research and Innovation at Kobe announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on “Treatment of inflammatory diseases, including autoimmune diseases, through the immunosuppressive activity of PD-1” conducted at the FBRI’s Dept. of Immunology, Institute of Biomedical Research and Innovation.

Meiji Seika Pharma Co., Ltd. announced that the first patient was dosed in Phase II clinical trial of ME3183, a selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis in the United States and Canada.

Meiji Seika Pharma Co., Ltd. announces the starting of operation of its US subsidiary, Meiji Pharma USA Inc., for expanding activities in the US with its initial focus on facilitating clinical development.